MX2017003269A - Detección de las proteínas mal plegadas. - Google Patents

Detección de las proteínas mal plegadas.

Info

Publication number
MX2017003269A
MX2017003269A MX2017003269A MX2017003269A MX2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A MX 2017003269 A MX2017003269 A MX 2017003269A
Authority
MX
Mexico
Prior art keywords
protein
misfolded
soluble
monomeric
sample
Prior art date
Application number
MX2017003269A
Other languages
English (en)
Spanish (es)
Inventor
K Vollrath Benedikt
M Lebovitz Russell
Shahnawaz Mohammad
Soto Jara Claudio
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2017003269A publication Critical patent/MX2017003269A/es

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/582Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
MX2017003269A 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas. MX2017003269A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462049306P 2014-09-11 2014-09-11
PCT/US2015/049844 WO2016040907A1 (en) 2014-09-11 2015-09-11 Detection of misfolded proteins

Publications (1)

Publication Number Publication Date
MX2017003269A true MX2017003269A (es) 2017-12-04

Family

ID=55454515

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017003269A MX2017003269A (es) 2014-09-11 2015-09-11 Detección de las proteínas mal plegadas.

Country Status (15)

Country Link
US (1) US20160077112A1 (enExample)
EP (2) EP3191599B1 (enExample)
JP (2) JP6980953B2 (enExample)
KR (1) KR102448128B1 (enExample)
CN (1) CN107208125A (enExample)
AU (1) AU2015314783B2 (enExample)
BR (1) BR112017004899A2 (enExample)
CA (1) CA2960830C (enExample)
ES (1) ES2953855T3 (enExample)
HR (1) HRP20231232T1 (enExample)
IL (2) IL251052B (enExample)
MX (1) MX2017003269A (enExample)
PL (1) PL3191599T3 (enExample)
SG (2) SG10202008464UA (enExample)
WO (1) WO2016040907A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040905A1 (en) 2014-09-11 2016-03-17 Board Of Regents Of The University Of Texas System Detection of misfolded alpha synuclein protein
GB201611840D0 (en) * 2016-07-07 2016-08-24 Univ Court Of The Univ Of Edinburgh The Alpha-synuclein detection assay
JP7136790B2 (ja) 2017-02-17 2022-09-13 ブリストル-マイヤーズ スクイブ カンパニー アルファ-シヌクレインに対する抗体およびその使用
IL270612B2 (en) 2017-05-16 2025-02-01 Amprion Inc Discovery of misfolded tau protein
CA3074914A1 (en) 2017-10-02 2019-04-11 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Assay for the detection of alpha-synuclein seeding activity associated with synucleinopathies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
MA51295A (fr) * 2017-12-21 2021-05-05 H Lundbeck As Dosage, procédé et traitement d'alpha-synucléinopathies
CN108088816A (zh) * 2018-01-23 2018-05-29 深圳市国赛生物技术有限公司 小型特定蛋白分析仪
GB201803553D0 (en) 2018-03-06 2018-04-18 Univ Newcastle Detection of pathological protein aggregation
US20190353669A1 (en) * 2018-05-16 2019-11-21 Amprion, Inc. Detection of Brain Injury or Neurological Disease using Tau Protein
JP7125544B2 (ja) 2018-09-21 2022-08-24 ディープマインド テクノロジーズ リミテッド 品質スコアの勾配を使用した反復的なタンパク質構造予測
JP7376040B2 (ja) * 2019-09-03 2023-11-08 国立大学法人京都工芸繊維大学 神経変性疾患におけるバイオマーカー分子の検出方法
AU2020343310A1 (en) * 2019-09-04 2022-03-24 Amprion, Inc. Alpha-synuclein detection using beads
KR102277871B1 (ko) * 2019-12-17 2021-07-15 원광대학교산학협력단 소변의 알파-씨누클레인 중합체 측정에 의한 파킨슨병 진단 정보의 수집방법 및 그 키트
WO2021198098A1 (en) 2020-04-03 2021-10-07 Universität Zürich Improved method of detecting biomarkers in a biological sample
CA3178674A1 (en) * 2020-05-18 2021-11-25 Amprion, Inc. Alpha-synuclein substrates and methods for making and using the same
CA3199642A1 (en) * 2020-11-21 2022-05-27 Shuwen Biotech Co. Ltd. Apparatus and method for detecting misfolded protein in biological sample
WO2022221876A1 (en) * 2021-04-15 2022-10-20 The Brigham And Women's Hospital, Inc. Digital protein misfolding assays
CN114199875B (zh) * 2022-02-18 2022-05-20 之江实验室 一种蛋白质多聚体是否可作为力缓冲剂的判断方法及装置

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2322660T3 (es) 2000-07-07 2009-06-24 Merck Serono Sa Diagnostico precoz de enfermedades conformacionales.
CA2433754A1 (en) 2001-01-03 2002-07-11 Ortho-Mcneil Pharmaceutical, Inc. Alpha synuclein aggregation assays
GB0203446D0 (en) * 2002-02-14 2002-04-03 Univ Lancaster Detection and/or monitoring of synuclein-related diseases
EP1820806A1 (en) * 2006-02-16 2007-08-22 Crossbeta Biosciences B.V. Affinity regions
BRPI0607350A2 (pt) * 2005-02-15 2009-09-01 Adlyfe Inc método para detecção da presença ou quantidade de uma proteìna erroneamente duplicada em uma amostra e kit
JP2009537153A (ja) * 2006-05-19 2009-10-29 アルニラム ファーマシューティカルズ, インコーポレイテッド AhaのRNAi調節およびその治療上の使用
US20080118938A1 (en) * 2006-09-06 2008-05-22 Lisbell Estrada Methods and Compositions for the Detection of Protein Folding Disorders
JP2010043865A (ja) * 2006-12-12 2010-02-25 Olympus Corp 異常型プリオンの検出方法
JP2013511734A (ja) * 2009-11-24 2013-04-04 プロビオドルグ エージー アルツハイマー病又は軽度認知障害の診断のための新規診断方法
US9133343B2 (en) * 2009-11-30 2015-09-15 Enzo Biochem, Inc. Dyes and compositions, and processes for using same in analysis of protein aggregation and other applications
US9910049B2 (en) * 2014-09-11 2018-03-06 Amprion, Inc. Detection of misfolded amyloid beta protein
EP2666020A1 (en) * 2011-01-18 2013-11-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods for amplification and detection of prions
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof

Also Published As

Publication number Publication date
HRP20231232T1 (hr) 2024-01-19
CA2960830C (en) 2023-09-05
PL3191599T3 (pl) 2023-12-27
US20160077112A1 (en) 2016-03-17
EP4292654A3 (en) 2024-01-03
IL251052B (en) 2022-05-01
AU2015314783B2 (en) 2021-10-21
WO2016040907A1 (en) 2016-03-17
CN107208125A (zh) 2017-09-26
SG11201701953RA (en) 2017-04-27
JP6980953B2 (ja) 2021-12-15
EP3191599C0 (en) 2023-08-02
EP4292654A2 (en) 2023-12-20
JP2017530373A (ja) 2017-10-12
BR112017004899A2 (pt) 2017-12-12
KR20170103741A (ko) 2017-09-13
CA2960830A1 (en) 2016-03-17
EP3191599A4 (en) 2018-03-14
EP3191599A1 (en) 2017-07-19
ES2953855T3 (es) 2023-11-16
SG10202008464UA (en) 2020-10-29
JP7104943B2 (ja) 2022-07-22
JP2022000629A (ja) 2022-01-04
IL291809B2 (en) 2023-06-01
IL291809A (en) 2022-06-01
EP3191599B1 (en) 2023-08-02
IL251052A0 (en) 2017-04-30
KR102448128B1 (ko) 2022-09-27
AU2015314783A1 (en) 2017-04-27

Similar Documents

Publication Publication Date Title
MX2017003269A (es) Detección de las proteínas mal plegadas.
MX2021006791A (es) Metodos y composiciones para detectar proteinas mal plegadas.
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX2019007653A (es) Métodos para la optimización de ensayos rápidos de susceptibilidad antimicrobiana.
EP3967769A3 (en) Lung cancer detection kit or device, and detection method
EP3757225A3 (en) Pancreatic cancer detection kit or device, and detection method
BR112016028944A2 (pt) kit ou dispositivo para a detecção de câncer do trato biliar e método de detecção
PH12019550236A1 (en) Detection of misfolded tau protein
EP4361290A3 (en) Compositions and methods for detecting a biological contaminant
WO2016209773A9 (en) Improved assays and methods for allergen detection
PH12015502849B1 (en) Biomarkers for cognitive dysfunction diseases and method for detecting cognitive dysfunction disease using biomarkers
WO2014207049A3 (de) Verfahren zur bestimmung von proteinaggregaten unter verwendung von oberflächen-fida
EA201892325A1 (ru) Композиции и способы детектирования белков клетки-хозяина
EP4067507A3 (en) Pna probes, kits and methods for detecting genotypes of human papillomavirus
MX2018004017A (es) Deteccion de beta amiloide por espectrometria de masas.
MY179845A (en) Specific biomarker set for non-invasive diagnosis of liver cancer
EP4513499A3 (en) Method and device for analyzing target analyte in sample
MX395376B (es) Dispositivo para la deteccion de proteinas mal plegadas y metodos de uso del mismo.
SG10201806729VA (en) Novel assay to detect human periostin
EA201700208A1 (ru) Способ и устройство для обнаружения малярии
MX2021009528A (es) Prueba de diagnostico basada en fragmento de rgma.
EP4407047A3 (en) Molecular detection of enterovirus and parechovirus
MX2018006146A (es) Modificación de diana para seguimiento y detección.
WO2014145243A3 (en) High resolution melting analysis assay for the detection of viral dna
MX2017008748A (es) Ensayo para detectar dipeptidil peptidasa iv (dpp-4) humana.